Carbon-11 Labeled Sarcosine in Prostate Cancer



Status:Completed
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:40 - Any
Updated:11/11/2017
Start Date:June 2015
End Date:February 8, 2017

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Biodistribution and Mechanism of Action of the 11C-labeled PET Tracer Sarcosine in Patients With Prostate Cancer as Well as Radiation Dosimetry, Plasma Pharmacokinetics and Biodistribution in Healthy Volunteers

Men with and without prostate cancer will have a PET/CT scan that measures the level of the
amino acid sarcosine. PET is a scanning method that uses short lived radioactivity.

Tissue levels of the amino acid sarcosine are elevated in prostate cancer compared to normal
prostate tissues and further increased in metastases from prostate cancer. This research
project is designed to test whether 11C-sarcosine (a chemical that is linked to short lived
radioactivity) would be useful to detect prostate cancer in men using PET/CT imaging. The
uptake and distribution of 11C-sarcosine in men with known or suspected prostate cancer will
be determined and compared with results from 11C-choline PET/CT.

Inclusion Criteria:

- Males 40 years of age or older

- Confirmed or suspected prostate cancer and will undergo a planned tissue biopsy of the
known or suspected tumor (Prostate Cancer Group 1 only)

Exclusion Criteria:

- Active malignancy (except basal cell or squamous cell skin cancer) within the last 2
years

- Body weight > 350 lbs (158 kg)

- Prisoners

- Subject not willing or able to sign informed consent
We found this trial at
1
site
University of Michigan Health Systems
Ann Arbor, Michigan 48109
Principal Investigator: Morand R. Piert, M.D.
Phone: 734-936-5388
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials